



# Nandu KS Thalange

**MBBS BSc, FRCP, FRCPC, FHEA, CCST**

<https://orcid.org/0000-0001-7925-625X>

Scopus ID 6507906972

Consultant Paediatric Endocrinologist

Genesis Healthcare Centre &

Clinical Professor of Paediatrics

Mohamed Bin Rashed University

Dubai, UAE

[n.thalange@genesis-dubai.com](mailto:n.thalange@genesis-dubai.com)

## Personal Details

<b>Date of Birth</b>	10th January 1964, Glasgow, UK
<b>Nationality</b>	British [Passport 548092471, exp 22/12/27]
<b>UK GMC No</b>	3284748 (full registration since 1/8/1989)
<b>UAE Professional License</b>	88632601-002 Consultant – Pediatric Endocrinology
<b>Address</b>	Apt 556, Hyatt Regency Creek Heights, Umm Hurair 2, Dubai, UAE 📍 <a href="mailto:nandu.thalange@dr.com">nandu.thalange@dr.com</a> 📞 +971 58 946 6920

## Profile

After graduating from King's College London in 1988, I specialized in paediatric endocrinology, beginning my career with a research fellowship in Manchester (1993–1996). During this time, I published several papers in high-impact journals on normal and abnormal childhood growth. After completing my clinical training in endocrinology, I became a consultant at the Norfolk & Norwich University Hospital (2002–2017), where I established the paediatric endocrinology service. I also initiated paediatric and neonatal research ultimately building a thriving research department, leading multiple university and industry-funded trials—including serving as Chief Investigator for two landmark multinational studies with Novo Nordisk. These trials led to the global approval of Levemir (2010) and Tresiba (2015), improving diabetes care for children worldwide.

In 2017, I moved to Dubai to establish the endocrine service at Al Jalila Children's Hospital, the UAE's first dedicated children's hospital. Today, the AJCH paediatric endocrinology department is very highly regarded. In 2023, we launched our paediatric endocrinology fellowship program and our first fellows graduated this year. I introduced various clinical advances, including AI-assisted bone age analysis, novel dynamic endocrine testing, cutting-edge genetic diagnostics (identifying two previously unknown disorders), and pioneering therapies in diabetes, lipid disorders, rare bone diseases, and obesity. In May 2025, I moved from Al Jalila to Genesis Healthcare Centre in Dubai, where I hope to build a new service with the same key elements of excellence and innovation.

Beyond clinical practice, I remain deeply committed to education and mentorship. Appointed Adjunct Professor of Paediatrics at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) in 2019, I was promoted to full Professor in 2023. I remain active in research, with an extensive publication record. I am a sought-after speaker, regularly presenting on endocrine and diabetes topics across the UAE, the Gulf region, and internationally.

Above all, my career has been driven by a desire to advance the field of paediatric endocrinology and improve outcomes for children and their families. It is my privilege to have mentored countless colleagues and made a lasting impact on the lives of many people around the world.

## Clinical Expertise

---

- Growth & Puberty
- Diabetes & insulin resistance
- Adrenal disorders
- Abnormal sexual development
- Thyroid conditions
- Pediatric lipid disorders
- Calcium & Bone
- Hypertension
- PCOS & Hyperandrogenism
- Child & Adolescent obesity
- Endocrine Genetics
- Endocrine effects of childhood cancer
- Skeletal dysplasias

## Qualifications

---

2017	FRCP, FRCPCH
2003	Fellow of Higher Education Academy (Membership No. 24961)
2002	Membership of Institute of Learning & Teaching (ILTM)
2001	CCST Paediatrics & Paediatric Endocrinology
1997	MRCPCH [Membership No. 10985]
1992	MRCP(UK) [Membership No. 50461]
1988	MB BS, King's College Hospital Medical School
1985	BSc (Biomedical Sciences), King's College, London

## Appointments

---

1.5.25 – Present	Consultant Paediatric Endocrinologist, Genesis Healthcare Centre, Dubai Science Park, Al Barsha, Dubai, UAE
22.5.19 - Present	Adjunct/Clinical Professor of Paediatrics, Mohammed Bin Rashid University, Dubai

## Previous Appointments

---

13.8.17 – 30.4.25	Consultant & Head of Paediatric Endocrinology, Al Jalila Children's Hospital, Dubai, UAE
1.4.02 – 23.4.17	Consultant Paediatric Endocrinologist Norfolk & Norwich University Hospitals NHS Foundation Trust
1.8.08 – 1.12.13	Chairman, Norfolk Child Death Overview Panel Norfolk & Norwich University Hospitals NHS Foundation Trust
21.11.00 – 31.3.02	Consultant Paediatrician/Paediatric Endocrinologist Surrey & Sussex NHS Trust
1.4.00 – 20.11.00	Health Improvement Programme Manager Norfolk Health Authority

## Training Posts

---

1.8.88-29.2.00	After junior posts at King's College Hospital and elsewhere, I took up a 3-year research post in paediatric endocrinology in Manchester, UK before moving to East Anglia to complete training in paediatrics and endocrinology, including a fellowship in public health.
----------------	--

## Research (since 2017)

- **Principal investigator: Ertugliflozin in Pediatric Type 2 Diabetes (10-17y)**  
A multinational RCT of ertugliflozin in addition to standard management of Type 2 diabetes. The study is now complete – AJCH was the leading site globally for number of enrolled patients.
- **Use of AI Bone Age Assessment in a UAE population**  
We analysed manual assessments of bone age of Arabic children compared to use of an AI bone age system, including the added utility and clinical application of the AI system. Published 2021.
- **Personal Experience and Physiological Responses of a Non-Professional Athlete Successfully Covering 620 Km in 7-Days by Foot Across the United Arab Emirates**  
I was brought into the project to analyse and interpret biochemical and endocrine data collected during the 7-day ultra-marathon and contributed to the study write up. Published 2022.
- **Medical student Research Projects**  
Several different research projects since 2018
- **Endocrine Fellow Research Projects**  
Multiple research projects completed and ongoing (from Jan 2023)

## Publications

### Publication Statistics (accessed 29 June 2025)

- 51 publications
- Statistics from Google Scholar
  - 1290 Citations
  - H-Index 17
  - I10 Index 24
  - Most cited paper (reference 26) has 285 citations

### Peer-Reviewed Publications: Author

1. Abdelgadir E, Rashid F, Bashier A, Zidan M, **Thalange N**, Hassanein M, Alawadi F. [Prevalence of overweight and obesity in children and adolescents: A large-scale population-based study](#). Diabetes Obes Metab. 2025 May 9. doi: 10.1111/dom.16449. PMID: 40345170  
*I conceived the pediatric arm of what was a larger study of adults with overweight & obesity, and played a major role in the writing process.*
2. Ramakrishna NB, Mohamad Sahari UB, Johmura Y, Ali NA, Alghamdi M, Bauer P, Khan S, Ordoñez N, Ferreira M, Pinto Basto J, Alkuraya FS, Faqeih EA, Mori M, Almontashiri NAM, Al Shamsi A, ElGhazali G, Abu Subieh H, Al Ojaimi M, El-Hattab AW, Said Al-Kindi SA, Alhashmi N, Alhabshan F, Al Saman A, Tfayli H, Arabi M, Khalifeh S, Taylor A, Alfadhel M, Jain R, Sinha S, Shenbagam S, Ramachandran R, Altunoğlu U, Jacob A, **Thalange N**, El Bejjani M, Perrin A, Shin JW, Al-Maawali A, Al-Shidhani A, Al-Futaisi A, Rabea F, Chekroun I, Almarri MA, Ohta T, Nakanishi M, Alsheikh-Ali A, Ali FR, Bertoli-Avella AM, Reversade B, Abou Tayoun A. [FBXO22 deficiency defines a pleiotropic syndrome of growth restriction and multi-system anomalies associated with a unique epigenetic signature](#). Am J Hum Genet. 2025 May 1;112(5):1233-1246. doi: 10.1016/j.ajhg.2025.03.013. Epub 2025 Apr 10. PMID: 40215970  
*I identified the index case as a likely novel genetic disorder which subsequently led to the recognition of FBXO22 deficiency as a previously unrecognised disease, with a further 15 families identified.*
3. Al Yaarubi S, Alsagheir A, Al Shidhani A, Alzelaye S, Alghazir N, Brema I, Alsaffar H, Al Dubayee M, Alshahrani A, Abdelmeguid Y, Omar OM, Attia N, Al Amiri E, Al Jubeh J, Algethami A, Alkhayyat H, Haleem

- A, Al Yahyaei M, Khochtali I, Babli S, Nugud A, **Thalange N**, Albalushi S, Hergli N, Deeb A, Alfadhel M. [Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa](#). Orphanet J Rare Dis. 2024 Mar 13;19(1):118. doi: 10.1186/s13023-024-03084-2. PMID: 38481246  
*I contributed a case to the cohort and was active in manuscript development*
4. Aldirawi M, Yavuz L, Ghoweba Y, Mohamedali S, Chencheri N, **Thalange N**. [Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation, Autonomic Dysregulation, and Neuroendocrine Tumor \(ROHHADNET\) Syndrome: A Case Report](#). Cureus. 2023 Jul 5;15(7):e41413. doi: 10.7759/cureus.41413. eCollection 2023 Jul. PMID: 37546061  
*I was involved in the diagnosis and management of the case and in the subsequent write-up*
5. El Naofal M, Ramaswamy S, Alsarhan A, Nugud A, Sarfraz F, Janbaz H, Taylor A, Jain R, Halabi N, Yaslam S, Alfalasi R, Shenbagam S, Rabea F, Bitzan M, Yavuz L, Wafadari D, Abulhoul H, Shankar S, Al Maazmi M, Rizk R, Alloub Z, Elbashir H, Babiker MOE, Chencheri N, AlBanna A, Sultan M, El Bitar M, Kherani S, **Thalange N**, Alshryda S, Di Donato R, Tzivinikos C, Majid I, Freeman AF, Gonzalez C, Khan AO, Hamdan H, Abuhammour W, AlAwadhi M, AlKhayat A, Alsheikh-Ali A, Abou Tayoun AN. [The genomic landscape of rare disorders in the Middle East](#). Genome Med. 2023 Jan 27;15(1):5. doi: 10.1186/s13073-023-01157-8. PMID: 36703223  
*With colleagues, I contributed many endocrine genetic cases and actively contributed clinical details and was involved in the write-up of the paper.*
6. Cromb D, Radomska M, **Thalange N**, Cawley P. [Fifteen-minute consultation: Investigation and management of hypoglycaemia in the term-born infant](#). Arch Dis Child Educ Pract Ed. 2024 Mar 19;109(2):73-81. doi: 10.1136/archdischild-2021-323568. PMID: 36347599  
*I contributed the endocrine input to the article and was heavily involved in the write-up.*
7. Boillat T, Kourie A, **Thalange N**, Du Plessis S, Loney T. [Guinness World Record: Personal Experience and Physiological Responses of a Non-Professional Athlete Successfully Covering 620 Km in 7-Days by Foot Across the United Arab Emirates](#). J Sports Sci Med. 2022 Jun 1;21(2):267-276. doi: 10.52082/jssm.2022.267. eCollection 2022 Jun. PMID: 35719239  
*I was responsible for analysing and interpreting the biochemical and hormone data and contributed actively to the study write-up*
8. EAEM Ahmed, AP D'Souza, M El Bejjani, **NK Thalange**. [Artificial Intelligence in the endocrine clinic: Automated bone age analysis in children from UAE](#). Medical Science and Discovery, 2021; 8(7):418-422. <http://dx.doi.org/10.36472/msd.v8i7.572>  
*I conceived the study and was responsible for the statistical analysis and write-up.*
9. Lane W, Lambert E, George J, Rathor N, **Thalange N**. [Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes](#). Clin Diabetes. 2021 Oct;39(4):347-357. doi: 10.2337/cd20-0117. PMID: 34866778
10. Hafsa Omer Sulaiman, **Nandu Kumar Sidramappa Thalange**. [Pycnodysostosis: A Growth Hormone Responsive Skeletal Dysplasia, AACE Clinical Case Reports, 2021](#), <https://doi.org/10.1016/j.aace.2021.02.006>
11. El Bejjani M, **Thalange N**. [Duodenal web masquerading as pseudohypoadosteronism of infancy](#). J. Clin. Translational Endocrinol: Case Reports. 2020 Mar 15, 100056 <https://doi.org/10.1016/j.jecr.2020.100056>
12. **Thalange N**, Gundgaard J, Parekh W, Tutkunkarda D. [Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK](#). BMJ Open Diabetes Res Care. 2019 Sep 3;7(1):e000664. doi: 10.1136/bmjdr-2019-000664. eCollection 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31543973>
13. **Thalange N**, Biester T, Danne T. [Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports](#). Diabetes Ther. 2019 Aug;10(4):1219-1237. doi: 10.1007/s13300-019-0641-3. Epub 2019 Jun 11. Review. <https://www.ncbi.nlm.nih.gov/pubmed/31187420>
14. **Thalange N**, Deeb L, Klingensmith G, Franco DR, Bardtrum L, Tutkunkardas D, Danne T. [The Rate of Hyperglycemia and Ketosis With Insulin Degludec-Based Treatment Compared With Insulin Detemir in Pediatric Patients With Type 1 Diabetes: An Analysis of Data From Two Randomized Trials](#). Pediatr

- Diabetes. 2019 Jan 22. doi: 10.1111/pedi.12821. [Epub 2019 Feb 10. PMID: 30666772], *Pediatr Diabetes*. 2019 May;20(3):314-320. doi: 10.1111/pedi.12821.
15. **Thalange N**, Aldhouse NVJ, Kitchen H, Howard D, Tutkunkardas D, Håkan-Bloch J. [Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK](#). *Diabetes Ther*. 2017 Oct;8(5):1065-1078. doi: 10.1007/s13300-017-0305-0. Epub 2017 Sep 13. PMID:28905317 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630560/>
  16. **Thalange N**, Bereket A, Jensen LB, Hiort LC, Peterkova V. [Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years](#). *Diabetes Ther*. 2016 Dec;7(4):713-724. Epub 2016 Sep 6. PMID:27600385
  17. Russell-Jones D, Danne T, Hermansen K, Niswender K, Robertson K, **Thalange N**, Vasselli JR, Yildiz B, Häring HU. [Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?](#) *Diabetes Obes Metab*. 2015 Oct;17(10):919-27. doi: 10.1111/dom.12493. Epub 2015 Aug 11. Review. PMID:25974283
  18. **Thalange N**, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T. [Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes](#). *Pediatr Diabetes*. 2015 May;16(3):164-76. doi: 10.1111/pedi.12263. Epub 2015 Feb 12. PMID: 25683037
  19. **Thalange N**, Bereket A, Larsen J, Hiort LC, Peterkova V. [Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial](#). *Diabet Med*. 2013 Feb;30(2):216-25. doi: 10.1111/dme.12041. PMID:23094597
  20. **Thalange N**, Bereket A, Larsen J, Hiort LC, Peterkova V. [Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus](#). *Pediatr Diabetes*. 2011 Nov;12(7):632-41. doi: 10.1111/j.1399-5448.2010.00750.x. Epub 2011 Mar 21. PMID:21418455
  21. Alam J, Ahlund S, **Thalange NK**, Clarke P. [The disparate psychological and social support available for parents in UK tertiary-level neonatal units](#). *Arch Dis Child Fetal Neonatal Ed*. 2010 Nov;95(6):F462. doi: 10.1136/adc.2010.187021. Epub 2010 Jun 15. PMID:20551189 <http://fn.bmj.com/content/95/6/F462.1.long>
  22. Ahlund S, Clarke P, Hill J, **Thalange NK**. [Post-traumatic stress symptoms in mothers of very low birth weight infants 2-3 years post-partum](#). *Arch Womens Ment Health*. 2009 Aug;12(4):261-4. doi: 10.1007/s00737-009-0067-4. Epub 2009 Mar 26. PMID:19322638
  23. Liivak K, Foster PJ, **Thalange N**, Tillmann V. *Horm Res*. [Short-term growth in children with congenital adrenal hyperplasia](#). 2009;71(3):142-7. doi: 10.1159/000197870. Epub 2009 Feb 3. PMID:19188738
  24. Zipitis CS, **Thalange N**. [Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations](#). *Eur J Pediatr*. 2007 Jun;166(6):585-8. Epub 2006 Sep 29. PMID:17008995
  25. Walton-Betancourth S, Martinelli CE, **Thalange NK**, Dyke MP, Acerini CL, White S, Camacho-Hübner C, Savage MO. [Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance](#). *J Endocrinol Invest*. 2007 May;30(5):439-41. PMID: 17598979
  26. Jackson LV, **Thalange NK**, Cole TJ. [Blood pressure centiles for Great Britain](#). *Arch Dis Child*. 2007 Apr;92(4):298-303. Epub 2006 Aug 11. Erratum in: *Arch Dis Child*. 2007 Jun;92(6):563. PMID: 16905566
  27. Shaw-Smith C, Willatt L, **Thalange N**. [Growth deficiency in oculodigitoesophagoduodenal \(Feingold\) syndrome--case report and review of the literature](#). *Clin Dysmorphol*. 2005 Jul;14(3):155-8. Review. PMID:15930908
  28. **Thalange N**, Gardner C, Reading R. [How is money spent on children's services?](#) *Child Care Health Dev*. 2004 Sep;30(5):503-5. PMID:15320926
  29. Duff C, Pencheon D, **Thalange N**, Kay L. [The Anglia Public Health Fellowship--an innovative training opportunity](#). *Arch Dis Child*. 2000 Nov;83(5):375-6. PMID:11040139
  30. Tillmann V, Gill MS, **Thalange NK**, Birkinshaw G, Price DA, Fraser WD, Clayton PE. [Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion](#)

- [in healthy prepubertal children](#). Growth Horm IGF Res. 2000 Feb;10(1):28-36. PMID:10753590 [http://www.growthhormoneigfresearch.com/article/S1096-6374\(99\)90136-3/pdf](http://www.growthhormoneigfresearch.com/article/S1096-6374(99)90136-3/pdf)
31. Gill MS, **Thalange** NK, Foster PJ, Tillmann V, Price DA, Diggie PJ, Clayton PE. [Regular fluctuations in growth hormone \(GH\) release determine normal human growth](#). Growth Horm IGF Res. 1999 Apr;9(2):114-22. PMID:10373344 [http://www.growthhormoneigfresearch.com/article/S1096-6374\(99\)90095-3/pdf](http://www.growthhormoneigfresearch.com/article/S1096-6374(99)90095-3/pdf)
  32. Tillmann V, **Thalange** NK, Foster PJ, Gill MS, Price DA, Clayton PE. [The relationship between stature, growth, and short-term changes in height and weight in normal prepubertal children](#). Pediatr Res. 1998 Dec;44(6):882-6. PMID:9853922 <https://www.nature.com/articles/pr1998577z>
  33. Eltringham IJ, **Thalange** N, Irish D, Issler H, Teall A. [A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia](#). Acta Paediatr. 1997 May;86(5):547-8. Erratum in: Acta Paediatr 1999 Mar;88(3):352. Irish D. PMID:9183498 <http://onlinelibrary.wiley.com/doi/10.1111/j.1651-2227.1997.tb08929.x/abstract>
  34. **Thalange** NK, Foster PJ, Gill MS, Price DA, Clayton PE. [Model of normal prepubertal growth](#). Arch Dis Child. 1996 Nov;75(5):427-31. PMID:8957957 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1511779/>
  35. **Thalange** NK, Price DA, Gill MS, Whatmore AJ, Addison GM, Clayton PE. [Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity](#). Pediatr Res. 1996 May;39(5):849-55. PMID: 8726240 <https://www.nature.com/articles/pr19962537>
  36. **Thalange** NK, Gill MS, Gill L, Whatmore AJ, Addison GM, Price DA, Clayton PE. [Infradian rhythms in urinary growth hormone excretion](#). J Clin Endocrinol Metab. 1996 Jan;81(1):100-6. PMID: 8550735 <https://academic.oup.com/jcem/article/81/1/100/2649329>

## Peer-Reviewed Publications: Collaborator

*I was an investigator for the studies leading to the publications below and contributed comments but was not involved in the write-up or study design*

37. Niechciał E, Acerini CL, Chiesa ST, Stevens T, Dalton RN, Daneman D, Deanfield JE, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dunger DB, Marcovecchio ML. Adolescent Type 1 Diabetes Cardio-renal Intervention Trial (AddIT) Study Group; Adolescent Type 1 Diabetes Cardio-renal Intervention Trial AddIT Study Group. [Medication Adherence During Adjunct Therapy with Statins and ACE Inhibitors in Adolescents With Type 1 Diabetes](#). Diabetes Care. 2020 Feb 27. pii: dc19o884. doi: 10.2337/dc19-o884. PMID: 32108022
38. Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ; PREDNOS Collaborative Group. [Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation](#). BMJ. 2019 May 23;365:l1800. doi: 10.1136/bmj.l1800. PMID: 31335316
39. Colver A, McConachie H, Le Couteur A, Dovey-Pearce G, Mann KD, McDonagh JE, Pearce MS, Vale L, Merrick H, Parr JR; Transition Collaborative Group. [A longitudinal, observational study of the features of transitional healthcare associated with better outcomes for young people with long-term conditions](#). BMC Med. 2018 Jul 23;16(1):111. doi: 10.1186/s12916-018-1102-y.
40. Marcovecchio ML, Chiesa ST, Armitage J, Daneman D, Donaghue KC, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dalton RN, Deanfield J, Dunger DB; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AddIT) Study Group. [Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial \(AddIT\)](#). Diabetes Care. 2018 Sep;41(9):1963-1969. doi: 10.2337/dc18-1125. Epub 2018 Jul 19.
41. Gray S, Cheetham T, McConachie H, Mann KD, Parr JR, Pearce MS, Colver A; Transition Collaborative Group. [A longitudinal, observational study examining the relationships of patient satisfaction with services and mental well-being to their clinical course in young people with Type 1 diabetes mellitus during transition from child to adult health services](#). Diabet Med. 2018 May 31. doi: 10.1111/dme.13698. [Epub ahead of print]

42. Colver A, Pearse R, Watson RM, Fay M, Rapley T, Mann KD, Le Couteur A, Parr JR, McConachie H; Transition Collaborative Group. [How well do services for young people with long term conditions deliver features proposed to improve transition?](#) BMC Health Serv Res. 2018 May 8;18(1):337. doi: 10.1186/s12913-018-3168-9.
43. Lambe T, Frew E, Ives NJ, Woolley RL, Cummins C, Brettell EA, Barsoum EN, Webb NJA; PREDNOS Trial Team. [Mapping the Paediatric Quality of Life Inventory \(PedsQL™\) Generic Core Scales onto the Child Health Utility Index-9 Dimension \(CHU-9D\) Score for Economic Evaluation in Children.](#) Pharmacoeconomics. 2018 Apr;36(4):451-465. doi: 10.1007/s40273-017-0600-7.
44. Colver A, McConachie H, Le Couteur A, Dovey-Pearce G, Mann KD, McDonagh JE, Pearce MS, Vale L, Merrick H, Parr JR; Transition Collaborative Group. [A longitudinal, observational study of the features of transitional healthcare associated with better outcomes for young people with long-term conditions.](#) BMC Med. 2018 Jul 23;16(1):111. doi: 10.1186/s12916-018-1102-y.
45. Marcovecchio ML, Chiesa ST, Armitage J, Daneman D, Donaghue KC, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dalton RN, Deanfield J, Dunger DB; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AddIT) Study Group. [Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial \(AddIT\).](#) Diabetes Care. 2018 Sep;41(9):1963-1969. doi: 10.2337/dc18-1125. Epub 2018 Jul 19.
46. Gray S, Cheetham T, McConachie H, Mann KD, Parr JR, Pearce MS, Colver A; Transition Collaborative Group. [A longitudinal, observational study examining the relationships of patient satisfaction with services and mental well-being to their clinical course in young people with Type 1 diabetes mellitus during transition from child to adult health services.](#) Diabet Med. 2018 May 31. doi: 10.1111/dme.13698.
47. Colver A, Pearse R, Watson RM, Fay M, Rapley T, Mann KD, Le Couteur A, Parr JR, McConachie H; Transition Collaborative Group. [How well do services for young people with long term conditions deliver features proposed to improve transition?](#) BMC Health Serv Res. 2018 May 8;18(1):337. doi: 10.1186/s12913-018-3168-9.
48. Lambe T, Frew E, Ives NJ, Woolley RL, Cummins C, Brettell EA, Barsoum EN, Webb NJA; PREDNOS Trial Team. [Mapping the Paediatric Quality of Life Inventory \(PedsQL™\) Generic Core Scales onto the Child Health Utility Index-9 Dimension \(CHU-9D\) Score for Economic Evaluation in Children.](#) Pharmacoeconomics. 2018 Apr;36(4):451-465. doi: 10.1007/s40273-017-0600-7.
49. Marcovecchio ML, Chiesa ST, Bond S, Daneman D, Dawson S, Donaghue KC, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dalton RN, Deanfield J, Dunger DB; AddIT Study Group. [ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.](#) N Engl J Med. 2017 Nov 2;377(18):1733-1745. doi: 10.1056/NEJMoa1703518. PMID:29091568
50. Merrick H, McConachie H, Le Couteur A, Mann K, Parr JR, Pearce MS, Colver A; Transition Collaborative Group. [Characteristics of young people with long term conditions close to transfer to adult health services.](#) BMC Health Serv Res. 2015 Sep 30;15:435. doi: 10.1186/s12913-015-1095-6. PMID:26424085
51. Cho YH, Craig ME, Davis EA, Cotterill AM, Couper JJ, Cameron FJ, Benitez-Aguirre PZ, Dalton RN, Dunger DB, Jones TW, Donaghue KC; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial. [Cardiac autonomic dysfunction is associated with high-risk albumin-to-creatinine ratio in young adolescents with type 1 diabetes in AddIT \(adolescent type 1 diabetes cardio-renal interventional trial\).](#) Diabetes Care. 2015 Apr;38(4):676-81. doi: 10.2337/dc14-1848. Epub 2015 Jan 8. PMID:25573882
52. Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, Dalton RN, Deanfield J, Dunger DB; AddIT Investigators. [Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial \(AddIT\): urinary screening and baseline biochemical and cardiovascular assessments.](#) Diabetes Care. 2014;37(3):805-13. doi: 10.2337/dc13-1634. Epub 2013 Nov 6. PMID:24198300  
Murphy HR, Wadham C, Hassler-Hurst J, Rayman G, Skinner TC; Families and Adolescents Communication and Teamwork Study (FACTS) Group. [Randomized trial of a diabetes self-management education and family teamwork intervention in adolescents with Type 1 diabetes.](#) Diabet Med. 2012 Aug;29(8):e249-54. doi: 10.1111/j.1464-5491.2012.03683.x. PMID: 22507080

53. Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group. [Adolescent type 1 Diabetes Cardio-renal Intervention Trial \(AddIT\)](#). BMC Pediatr. 2009 Dec 17;9:79. doi: 10.1186/1471-2431-9-79. PMID:20017932

## Other Publications

---

21. **Thalange NKS** (published anonymously). [A memorable patient. Someone else's problem](#). BMJ, 317: 194 1998 July 18. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1113541/>
22. Gill MS, **Thalange NKS**, Diggle PJ and Clayton PE. [Rhythms in urinary growth hormone \(GH\), insulin-like growth factors-I \(IGF-I\) and IGF binding protein-3 excretion in children with normal stature](#). Saltation and Stasis in Human Growth Development: evidence, methods and theory, ed. M. Lampl, 59-70. London: Smith-Gordon, 1999. <http://www.sciencedirect.com/science/article/pii/B9780121566517500137>
23. Gibbs S, **Thalange NKS**. [Public health is good for you](#). BMJ classified, Career Focus. 318: Saturday 16 October 1999 <http://www.bmj.com/content/319/7216/S2-7216>
24. [Saunders' Pocket Essentials of Paediatrics](#). **Thalange NKS**, Beach RC, Kinnaird T, Holmes P (Editors), Elsevier, Edinburgh, 2006
25. Mancel B, **Thalange NKS**, McGlashan K. [A Sixteen-Year-Old in PVS Who Develops Cushing's Disease: Medical and Ethical Issues](#). Adv Clin Neurosci Rehab. 7(1):17-8, 2007 Mar/Apr
26. Saunders' Pocket Essentials of Paediatrics (second Ed), **Thalange NKS**, Beach RC, Booth D, Jackson LJ. (Editors), Elsevier, Edinburgh, Dec 2012 <https://www.us.elsevierhealth.com/essentials-of-paediatrics-9780702043598.html>
27. Effective trials in diabetes: a pediatric perspective. **Thalange NKS**. Diabetes Manag. (2015) 5(5), 337-340 <http://www.openaccessjournals.com/articles/effective-trials-in-diabetes-a-pediatric-perspective.pdf>
28. [Genetics in Medicine](#). Barbara Jennings, Gavin Willis, and **Nandu Thalange**. Oxford University Press. July 2020. ISBN: 9780198841555
29. Thalange N. [Flexibility is key in treating children with type 1 diabetes](#). Research Outreach, 116; Aug 27 2020. DOI: 10.32907/RO-116-7881
30. [Pediatric Orthopedics for Primary Healthcare: Evidence-Based Practice](#) 1st ed. 2021 Edition, Sattar Alshryda, Lisa Jackson, **Nandu Thalange**, Ali AlHammadi. Springer; June 2, 2021. ISBN: ISBN: 978-3-030-65214-2

## Conference Abstracts (2020-2025)

---

31. M Awad, N Thalange. [Self-resolving regional lipodystrophy secondary to somatrogen therapy: a case report](#). Endocrine Abstracts 110, 2025
32. R Mohamed, A Jacob, M El-Abiary, N Thalange, S Ehtisham. [A shared GHSR gene variant in children with short stature and growth hormone deficiency: potential clinical relevance](#). Endocrine Abstracts 110, 2025
33. W Kaplan, A Elherbish, A AlJneibi, A Alsagheir, A Almutair, A Farooque, Asma Deeb, Abbas Bassam Bin, Jubeh Jamal Al, Najya Attia, Nandu Thalange, Al Remeithi Sareea Salem, Paul Dimitri, Octavio Rivera-Romero, Ekaterina Koledova. [Integrating patient-generated health data into growth hormone therapy: perspectives from the paediatric endocrinologists in the gulf cooperation council](#). Endocrine Abstracts 110, 2025
34. A Jacob, M Thyagarajan, R Ghanim, M Awad, M Bitzan, N Thalange. [Abstract# 1910804 Conn Syndrome: A Rare Cause of Childhood Hypertension](#). AACE Endocrine Practice 30 (12), S22, 2024.
35. R Ghanim, Z Abadelah, S Khattab, N Thalange. [The iPhone Measure app as a measuring device for the height in pediatrics: a reliability study](#). Hormone Research In Paediatrics 97, 319-320, 2024.
36. M Mustafa, N Thalange, F Rabea, Z Mughal, A Abou Tayoun. [A Novel homozygous founder mutation in UFSP2 is associated with a distinct form of skeletal dysplasia in Emiratis](#). Hormone Research In Paediatrics 97, 481 2024

37. Anju Jacob, Sarah Gharaibeh, Ruchi Jain, Alan Taylor, Shruti Shenbagam, Ahmad AbuTayoun, Mohamed Elabiary, Nandu Thalange. [The genomic landscape of children with short stature presenting to a tertiary hospital in UAE](#). Hormone Research In Paediatrics; 97, 511-512; 2024.
38. M Awad, N Thalange, M El Abiary. [Mutations in THRB gene are associated with combined congenital hypothyroidism and TSH resistance](#). Hormone Research In Paediatrics; 97, 529-529, 2024
39. A Jacob, N Shaukat, R Jain, N Thalange. [Genetic Causes of Obesity in children from a tertiary hospital in UAE](#). Hormone Research In Paediatrics 97, 385-385, 2024
40. A Jacob, N Shaukat, A Dsouza, L Almarzooqi, N Thalange. [46, XX DSD secondary to Maternal Adrenocortical Tumor](#). Hormone Research In Paediatrics 97, 533-533, 2024.
41. R Ghanim, S Ehtisham, Z Mughal, N Thalange. [Comprehensive Evaluation of Anastrozole in Pediatric Height Management and Bone Health-A Real World Data](#). Hormone Research In Paediatrics 97, 140-141, 2024.
42. A Jacob, N Thalange. Abstract# 1604700: [A Heterozygous LDLR Mutation in 2 Young Siblings Presenting to a Tertiary Children's Hospital in United Arab Emirates](#). Endocrine Practice 29 (12), S158, 2023.
43. A Jacob, N Thalange. [Case Report: Massive Obesity secondary to a Homozygous MC4R mutation in a 3-year-old Boy](#). Hormone Research In Paediatrics 96, 505-506, 2023.
44. R Ghanim, AP D'Souza, A Qazi, C Baldrighi, N Thalange. [Case Report: Carney Complex presenting as Bilateral Large Cell Calcifying Sertoli Cell Tumours Treated with Anastrozole](#). Hormone Research In Paediatrics 96, 347-348, 2023.
45. A Jacob, N Thalange, M El Bejjani. [Abstract# 1325612: A Novel Methylation Disorder Resulting in Profound Growth Failure Associated With a Mutation in FBXO22](#). Endocrine Practice 28 (12), S50, 2022
46. A Jacob, M Elbejjani, A Qazi, N Thalange. [A rare cause of precocious puberty: Hepatoblastoma](#). Hormone Research In Paediatrics 95 (Suppl 2), 586-587, 2022.
47. AA Nugud, NK Thalange. [AAACE2021-A-1102: Growth Hormone Deficiency in Patient with De Novo Mutation in SHOC2 Causing Noonan Syndrome-Like Disorder with Loose Anagen Hair, and Castelman Syndrome](#). AAACE Endocrine Practice 27 (12), S18-S19, 2021
48. A Jacob, M El Bejjani, N Thalange. [AAACE2021-A-1060: Persistent Ketotic Hypoglycemia in a 2-Year Old Child with Treated Growth Hormone Deficiency](#). Endocrine Practice 27 (12), S43-S44, 2021.

## Membership of Learned Societies

---

Royal College of Physicians of London (1992)

Royal College of Paediatrics and Child Health (1997)

British Society for Paediatric Endocrinology & Diabetes (1994)

British Society for the History of Paediatrics & Child Health (2002)

Institute of Learning & Teaching (2002)

Higher Education Academy (2003)

Arab Society for Pediatric Endocrinology 2017

## References available on request